Vanguard Group’s Fulgent Genetics FLGT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | $33.1M | Buy |
1,260,014
+80,760
| +7% | +$2.09M | ﹤0.01% | 2388 |
|
|
2025
Q3 | $26.7M | Buy |
1,179,254
+13,295
| +1% | +$274K | ﹤0.01% | 2479 |
|
|
2025
Q2 | $23.2M | Sell |
1,165,959
-2,015
| -0.2% | -$39.3K | ﹤0.01% | 2489 |
|
|
2025
Q1 | $19.7M | Sell |
1,167,974
-223,100
| -16% | -$3.8M | ﹤0.01% | 2507 |
|
|
2024
Q4 | $25.7M | Sell |
1,391,074
-57,597
| -4% | -$1.12M | ﹤0.01% | 2469 |
|
|
2024
Q3 | $31.5M | Buy |
1,448,671
+13,246
| +0.9% | +$296K | ﹤0.01% | 2385 |
|
|
2024
Q2 | $28.2M | Buy |
1,435,425
+10,977
| +0.8% | +$229K | ﹤0.01% | 2396 |
|
|
2024
Q1 | $30.9M | Buy |
1,424,448
+8,257
| +0.6% | +$205K | ﹤0.01% | 2386 |
|
|
2023
Q4 | $40.9M | Buy |
1,416,191
+22,480
| +2% | +$601K | ﹤0.01% | 2270 |
|
|
2023
Q3 | $37.3M | Buy |
1,393,711
+3,139
| +0.2% | +$107K | ﹤0.01% | 2268 |
|
|
2023
Q2 | $51.5M | Buy |
1,390,572
+12,321
| +0.9% | +$429K | ﹤0.01% | 2169 |
|
|
2023
Q1 | $43M | Sell |
1,378,251
-15,583
| -1% | -$502K | ﹤0.01% | 2242 |
|
|
2022
Q4 | $41.5M | Buy |
1,393,834
+28,098
| +2% | +$1.01M | ﹤0.01% | 2274 |
|
|
2022
Q3 | $52.1M | Buy |
1,365,736
+32,173
| +2% | +$1.61M | ﹤0.01% | 2162 |
|
|
2022
Q2 | $72.7M | Sell |
1,333,563
-5,808
| -0.4% | -$319K | ﹤0.01% | 2001 |
|
|
2022
Q1 | $83.6M | Buy |
1,339,371
+26,731
| +2% | +$1.76M | ﹤0.01% | 2049 |
|
|
2021
Q4 | $132M | Buy |
1,312,640
+4,906
| +0.4% | +$431K | ﹤0.01% | 1831 |
|
|
2021
Q3 | $118M | Buy |
1,307,734
+28,175
| +2% | +$2.56M | ﹤0.01% | 1907 |
|
|
2021
Q2 | $118M | Buy |
1,279,559
+228,044
| +22% | +$18.2M | ﹤0.01% | 1911 |
|
|
2021
Q1 | $102M | Buy |
1,051,515
+158,979
| +18% | +$16.4M | ﹤0.01% | 1938 |
|
|
2020
Q4 | $46.5M | Buy |
892,536
+49,910
| +6% | +$2.09M | ﹤0.01% | 2240 |
|
|
2020
Q3 | $33.7M | Buy |
842,626
+256,644
| +44% | +$8.03M | ﹤0.01% | 2217 |
|
|
2020
Q2 | $9.38M | Buy |
585,982
+96,243
| +20% | +$1.47M | ﹤0.01% | 2807 |
|
|
2020
Q1 | $5.27M | Sell |
489,739
-25,644
| -5% | -$357K | ﹤0.01% | 2952 |
|
|
2019
Q4 | $6.65M | Buy |
515,383
+147,732
| +40% | +$1.76M | ﹤0.01% | 3061 |
|
|
2019
Q3 | $3.82M | Buy |
367,651
+215,450
| +142% | +$2.04M | ﹤0.01% | 3237 |
|
|
2019
Q2 | $1.02M | Hold |
152,201
| – | – | ﹤0.01% | 3673 |
|
|
2019
Q1 | $906K | Buy |
152,201
+1,200
| +0.8% | +$5.5K | ﹤0.01% | 3652 |
|
|
2018
Q4 | $479K | Sell |
151,001
-45,592
| -23% | -$160K | ﹤0.01% | 3740 |
|
|
2018
Q3 | $773K | Buy |
196,593
+2,100
| +1% | +$8.99K | ﹤0.01% | 3777 |
|
|
2018
Q2 | $805K | Buy |
194,493
+400
| +0.2% | +$1.58K | ﹤0.01% | 3742 |
|
|
2018
Q1 | $772K | Buy |
194,093
+8,396
| +5% | +$37K | ﹤0.01% | 3708 |
|
|
2017
Q4 | $814K | Sell |
185,697
-64,941
| -26% | -$249K | ﹤0.01% | 3656 |
|
|
2017
Q3 | $1.19M | Buy |
250,638
+16,903
| +7% | +$97.2K | ﹤0.01% | 3545 |
|
|
2017
Q2 | $1.49M | Sell |
233,735
-8,770
| -4% | -$70.7K | ﹤0.01% | 3468 |
|
|
2017
Q1 | $2.65M | Buy |
242,505
+14,878
| +7% | +$176K | ﹤0.01% | 3292 |
|
|
2016
Q4 | $2.63M | Buy |
+227,627
| New | +$2.15M | ﹤0.01% | 3268 |
|
Other funds holding FLGT
RI
Vanguard Group's FLGT Position: Q4 2025 in Review
Vanguard Group increased its Fulgent Genetics (FLGT) stake by 6.8% in Q4 2025, buying an estimated $2.09M and bringing the position to 1,260,014 shares worth $33.1M. The position accounts for ﹤0.01% of the portfolio, ranked #2388.
Vanguard Group first reported a position in FLGT in Q4 2016 and has held it in 37 quarters since. The position peaked at $132M in Q4 2021. 179 funds tracked by Wall St. Rank hold FLGT as of Q4 2025.
- Vanguard Group held 1,260,014 shares of Fulgent Genetics worth $33.1M as of Q4 2025.
- Vanguard Group bought 80,760 Fulgent Genetics shares in Q4 2025, an estimated $2.09M.
- Fulgent Genetics made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2388 holding.
- Vanguard Group first reported a position in Fulgent Genetics in Q4 2016 and has held it in 37 quarters since.
- Vanguard Group's Fulgent Genetics position peaked at $132M in Q4 2021.
- 179 funds tracked by Wall St. Rank held Fulgent Genetics as of Q4 2025.
Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.